Recruiting
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants - IM038-1007
Actualizada: 13 septiembre, 2023 | ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Fase
Géneros
Rango de edad
Ubicación (es)
Recruiting
Opciones de tratamiento
Inclusion Criteria: - Healthy male participants without clinically significant deviation from normal in medical history, electrocardiogram (ECG), clinical laboratory determinations, and Day -1 physical examination. - Body mass index of 18.0 to 35.0 kilograms/meter square (kg/m^2), inclusive, and total body weight ≥ 50 kg Exclusion Criteria: - Any significant acute or chronic medical illness as determined by the investigator. - A history of clinically significant hepatic or pancreatic disease (Gilbert's syndrome is permissible). - Current or recent (within 3 months prior to study treatment administration) gastrointestinal disease that could impact upon the absorption, distribution, metabolism, or excretion of study treatment as determined by the investigator. Note: Other protocol-defined inclusion/exclusion criteria apply.
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
